The research, led by Cassidy A. Guida of Wake Forest University School of Medicine, pooled individual participant data from seven randomized caloric restriction trials involving 829 older adults. The trials, drawn from Wake Forest’s Integrated Aging Studies Databank and Repository, ranged in duration from six to eighteen months and enrolled participants with overweight or obesity, many with coexisting conditions such as cardiovascular disease, knee osteoarthritis, or low physical function. Participants averaged 67.5 years of age, roughly two-thirds were women, and mean body mass index values ranged from about 30 to 36 kilograms per square meter across the contributing studies.

The biomarker index at the heart of the study was constructed following the framework of the TAME, or Targeting Aging with Metformin, Biomarkers Workgroup, which identified blood-based measures that best capture core hallmarks of aging while remaining practical for large clinical trials. Six biomarkers made the cut: C-reactive protein, interleukin-6, cystatin C, insulin, growth differentiation factor-15, and tumor necrosis factor-receptor 1. Together, these markers span inflammation, insulin signaling, metabolic stress, and renal function, domains that animal research has consistently tied to the biology of dietary restriction. Each participant’s change in each biomarker was converted to a quintile score, and the scores were summed into a single composite index, an approach intended to smooth out the inter-individual variability that plagues single-biomarker measures.

The results were strikingly consistent. Across the pooled trials, randomization to caloric restriction produced an average weight loss of 7.9 kilograms, compared with 1.2 kilograms in control groups, and was associated with a 2.2-point improvement in the composite biomarker quintile score, a statistically robust effect with every contributing study showing a benefit. Reductions were most pronounced in C-reactive protein, interleukin-6, insulin, and TNF-receptor 1, while cystatin C and GDF-15 showed more heterogeneity across studies. The consistency of the direction of effect, even in trials with different designs, intervention intensities, and follow-up periods, strengthens the case that the index is genuinely responsive to caloric restriction rather than an artifact of any single trial.

The most consequential question, however, was not whether caloric restriction improved the index, but how. Critics have long argued that the benefits of dietary restriction simply reflect weight loss itself rather than any special biology of eating less. To address this, the researchers performed a formal mediation analysis exploiting the randomization design: because assignment to caloric restriction was random, any relationship between the intervention and downstream outcomes could be decomposed into a portion mediated by weight loss and a residual, weight-independent effect.

The answer was nuanced. Roughly 48.5 percent of the effect of caloric restriction on the composite biomarker index was explained by the amount of weight participants lost. When change in body weight was added to the statistical model, the effect of caloric restriction shrank from minus 2.2 to minus 1.2 points, but it did not disappear. Conversely, the effect of weight loss itself dropped from 0.22 to 0.16 points per kilogram when caloric restriction assignment was accounted for. Both pathways, in other words, contribute independently. The residual direct effect of caloric restriction, at minus 1.34 points for the composite score, remained statistically significant, indicating that something beyond the number on the scale is driving the improvement.

That something may involve the nutrient-sensing pathways that decades of animal research have implicated in dietary restriction’s life-extending effects. Caloric restriction is known to activate AMP-activated protein kinase and sirtuin 1 while suppressing mechanistic target of rapamycin signaling, a trio of molecular switches that promotes autophagy, the cellular housekeeping that clears damaged proteins and organelles. These same pathways temper oxidative stress and chronic low-grade inflammation, providing a plausible biological bridge to the observed reductions in C-reactive protein and interleukin-6 that occurred independent of weight loss. Mitochondrial adaptations and shifts in innate immune cell metabolism may similarly underlie the insulin improvements seen in the trials, though the authors caution that these mechanisms were not directly measured and remain inferential.

The findings resonate with a broader pattern emerging across geroscience. In the landmark CALERIE trial, two years of roughly 12 percent caloric restriction in younger, normal-weight adults improved cardiometabolic risk factors and slowed the pace of aging as measured by the DunedinPACE epigenetic algorithm, yet did not change static estimates of biological age. Meanwhile, secondary analyses of the SELECT trial of semaglutide found that cardiovascular benefits persisted across weight categories and were driven in part by reductions in waist circumference rather than body weight alone. Together with the new pooled analysis, these results suggest that interventions targeting energy balance act through weight-dependent and weight-independent routes, and that responsive biomarker indices may capture these effects more faithfully than fixed biological age estimates.

The study has limitations worth noting. All seven trials came from a single research network with overlapping investigators and similar protocols, which may limit generalizability to more diverse populations. The intervention durations were relatively short, so the results demonstrate that caloric restriction favorably modifies aging-related biomarkers rather than proving reductions in disease or mortality. Individual components of the index, particularly GDF-15 and cystatin C, behaved inconsistently across studies, and whether the composite index correlates with epigenetic clocks or validated frailty measures remains an open question for future work.

Still, the implications are considerable. With roughly 40 percent of American adults aged 65 and older now living with obesity, and obesity a major driver of multimorbidity, frailty, and late-life disability, interventions that target the biology of aging hold enormous public health promise. The demonstration that a practical, six-marker blood index can detect intervention effects across heterogeneous trials positions such indices as potential surrogate endpoints for geroscience trials, potentially accelerating the testing of strategies to extend healthspan. And the finding that about half of caloric restriction’s benefit operates through pathways that weight loss alone cannot explain reinforces a message that biologists have been echoing from animal studies for decades: eating less does something to the machinery of aging that goes far beyond slimming down.

Subject of Research: The effect of caloric restriction on biological aging measured by a composite blood biomarker index in older adults

Article Title: Impact of caloric restriction on biological aging: insights from a composite biomarker index in older adults

Article References: Guida, C. A., Hsu, F.-C., Neiberg, R., Semelka, C., Chen, H., Kramer, P., Houston, D. K., Nicklas, B., Kritchevsky, S. B., & Miller, M. E. (2026). Impact of caloric restriction on biological aging: insights from a composite biomarker index in older adults. GeroScience. https://doi.org/10.1007/s11357-026-02529-9

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02529-9

Keywords: caloric restriction, biological aging, biomarkers, geroscience, older adults, inflammation, insulin, weight loss, mediation analysis, CRP, IL-6, Impact